無料セミナー : 2018年11月27日『オンコロジーにおける遺伝子治療・CAR-T細胞療法』 DelveInsight Business Research LLP共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の前立腺癌診断および治療市場:種類、診断法、治療法、地域別 - 成長、動向、予測(2018年〜2023年)

Global Prostate Cancer Diagnostics & Therapy Market - Segmented by Type, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)

発行 Mordor Intelligence LLP 商品コード 660546
出版日 ページ情報 英文 112 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.36円で換算しております。
Back to Top
世界の前立腺癌診断および治療市場:種類、診断法、治療法、地域別 - 成長、動向、予測(2018年〜2023年) Global Prostate Cancer Diagnostics & Therapy Market - Segmented by Type, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日: 2018年05月01日 ページ情報: 英文 112 Pages
概要

世界の前立腺癌診断および治療市場は、2018年から2023年にかけて6.1%のCAGRで推移することが予測されています。2016年においては、収益ベースで最大のシェアを占めた北米地域が市場を牽引しました。

当レポートでは、世界の前立腺癌診断および治療市場を調査し、市場の概要、タイプ・診断法・治療法・地域別の市場規模の推移と予測、市場動向、成長要因・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 成長要因、阻害要因、市場機会、課題

  • 市場の成長要因
    • 前立腺癌の罹患率の高さ
    • 治療薬の革新とゲノミクスおよびプロテオミクス領域における発展
    • 医薬品開発分野における公的部門および民間部門の資金調達の増加
    • 癌・腫瘍診断および治療薬の技術的発展
  • 市場の阻害要因
    • 診断検査に関連するコストの高さ
    • 臨床試験の成功率の低さ
    • 治療の副作用
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 種類別
    • 良性前立腺肥大症
    • 前立腺腺癌
    • 小細胞癌
    • その他
  • 診断法別
    • 細胞生検
    • デジタル直腸検査
    • 臨床検査
    • 診断イメージング
  • 治療法別
    • 化学療法
    • 小線源治療
    • 放射線療法
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • 合併・買収分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要プレーヤー

  • Abbott
  • AstraZeneca
  • アステラス製薬
  • Bayer AG
  • BioMark Diagnostics Inc.
  • Sanofi
  • Ipsen
  • TOLMAR Pharmaceuticals, Inc.
  • Indevus Pharmaceuticals Inc.
  • Dendreon Inc.
  • その他の企業

第10章 市場の将来展望

目次
Product Code: 47468

The prostate cancer diagnostics market is expected to witness a CAGR of 6.1% during the forecast period (2018-2023). North America was leading the global market with the largest revenue share in 2016.

High Prevalence Rate of Prostate Cancer

The high prevalence rate of prostate cancer is a key factor, which is driving the global market for the prostate cancer. Prostate cancer is the second-leading cause of death in the United States. According to National Cancer Institute, it is estimated that there were around 161,360 new cases of prostate cancer and an estimated 26,730 people will die due to it. Based on these statistics, we can see that the prevalence rate of prostate cancer is increasing across the world and hence, it is driving the market.

The other factors include innovation in drugs and developments in genomics and proteomics, rise in the funding in both public and private sectors, in the field of drug development, technological advancement in oncology diagnostics and therapeutics area.

Increasing Cost of the Prostate Cancer Drugs

There are many new drugs that have increased the life expectancy of prostate cancer patients and have been approved by the Food & Drug Administration. But these drugs are having a high cost, which is a threat for the patients and the insurers, both. These expensive drugs are not being paid by the insurance companies and the reimbursement level for them is very low. Hence, only few people are capable of affording these drugs. Therefore, because of this high cost, the use of generic drugs is more, and hence, it is hindering the growth of the prostate cancer drugs market.

The other factors include, low success rate of clinical trials and side effects of the treatments.

The United States Dominates the Market

North America is the leading global market with the largest revenue share in 2016. Due to the rising prevalence of the diseases and high mortality rate of the prostate cancer in the United States, North America is dominating the market. Asia-Pacific is also projected to be the fastest growing region, due to the improving healthcare infrastructure and the growing investments by the key market players.

Key Developments in the Market:

February 2017: AstraZeneca entered into an agreement with TerSera Therapeutics LLC, for Zoladex in the United States and Canada. Zoladex is an injectable luteinising hormone-releasing agonist, which is used to treat prostate cancer, breast cancer, and certain benign gynaecological disorders.

Major Players: ABBOTT, ASTRAZENECA, ASTELLAS PHARMA INC., BAYER AG, BIOMARK DIAGNOSTICS INC., SANOFI, IPSEN, TOLMAR PHARMACEUTICALS INC., INDEVUS PHARMACEUTICALS INC., DENDREON INC., FERRING BV, AND CELLANYX LLC amongst others.

Reasons to Purchase this Report:

Current and future market outlook for prostate cancer diagnostics, in the developed and emerging markets

Analyze various perspectives on the market, with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness the fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players

3 months analyst support, along with the market estimate sheet (in Excel)

Customization of the Report:

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porters Five Force Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry Within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 High Disease Prevalence Rate of Prostate Cancer
    • 6.1.2 Innovation in Drugs and Developments in Genomics and Proteomics
    • 6.1.3 Rise in the Funding in Both Public and Private Sector in the Field of Drug Development
    • 6.1.4 Technological Advancement in Oncology Diagnostics & Therapeutics Area
  • 6.2 Market Restraints
    • 6.2.1 High Cost Associated with Diagnostic Tests
    • 6.2.2 Low Success Rate of Clinical Trials
    • 6.2.3 Side Effects of Treatments
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Type
    • 7.1.1 Benign Prostatic Hyperplasia
    • 7.1.2 Prostatic Adenocarcinoma
    • 7.1.3 Small Cell Carcinoma
    • 7.1.4 Others
  • 7.2 By Diagnosis
    • 7.2.1 Tissue Biopsy
    • 7.2.2 Digital Rectal Examination
      • 7.2.2.1 Transrectal Ultrasound
      • 7.2.2.2 Transrectal Ultrasonography
    • 7.2.3 Clinical Laboratory Examination
      • 7.2.3.1 Prostate-Specific Antigen Testing
      • 7.2.3.2 Urine Testing
      • 7.2.3.3 Blood Testing
    • 7.2.4 Diagnostic Imaging
  • 7.3 By Treatment
    • 7.3.1 Chemotherapy
    • 7.3.2 Brachytherapy
    • 7.3.3 Radiation therapy
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States
      • 7.4.1.2 Canada
      • 7.4.1.3 Mexico
    • 7.4.2 Europe
      • 7.4.2.1 France
      • 7.4.2.2 Germany
      • 7.4.2.3 United Kingdom
      • 7.4.2.4 Italy
      • 7.4.2.5 Spain
      • 7.4.2.6 Rest of Europe
    • 7.4.3 Asia-pacific
      • 7.4.3.1 China
      • 7.4.3.2 Japan
      • 7.4.3.3 India
      • 7.4.3.4 Australia & New Zealand
      • 7.4.3.5 South Korea
      • 7.4.3.6 Rest of Asia-Pacific
    • 7.4.4 Middle East & Africa
      • 7.4.4.1 GCC
      • 7.4.4.2 South Africa
      • 7.4.4.3 Rest of the Middle East & Africa
    • 7.4.5 South America
      • 7.4.5.1 Brazil
      • 7.4.5.2 Argentina
      • 7.4.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Abbott
  • 9.2 AstraZeneca
  • 9.3 Astellas Pharma Inc
  • 9.4 Bayer AG
  • 9.5 BioMark Diagnostics Inc.
  • 9.6 Sanofi
  • 9.7 Ipsen
  • 9.8 TOLMAR Pharmaceuticals, Inc.
  • 9.9 Indevus Pharmaceuticals Inc.
  • 9.10 Dendreon Inc.
  • 9.10 List Not Exhaustive

10. Future of the Market

Back to Top